NEW HAVEN, Conn., Nov. 6,
2019 /PRNewswire/ -- Kleo Pharmaceuticals, Inc., an
immuno-oncology company developing next-generation, fully synthetic
bispecific compounds designed to emulate or enhance the activity of
biologics, announced today that two abstracts have been accepted
for presentation at the 61st annual American Society of Hematology
(ASH) meeting and exposition being held December 7-10 in Orlando, FL.
The posters will showcase the strong preclinical data of Kleo's
most advanced Antibody Recruiting Molecules (ARM) in development,
which target CD38, a cell surface protein that is highly
expressed by malignant plasma cells in multiple myeloma (MM)
patients. ARMs are bispecific molecules that redirect a patient's
own polyclonal antibodies to target tumor cells. They are comprised
of a proprietary antibody-binding domain linked to a highly
specific tumor-binding domain. They work by creating a bridge
between antibodies and cancer cells that leads to immune-mediated
killing of the tumor.
"Kleo is honored to present preclinical proof-of-concept data
for our CD38-ARMs at ASH, which supports the advancement of this
exciting and novel technology platform into the clinic," said
Doug Manion, Kleo's Chief Executive
Officer. "Our highly modular ARM platform has demonstrated clear
differentiation from therapeutic monoclonal antibodies and broad
applicability in a number of oncology and non-oncology indications.
We are scheduled to file our first investigational new drug (IND)
application in 1Q 2020."
Details of the poster presentations are as follows:
Title: A Novel Class of Bifunctional Immunotherapeutic
That Exploit a Universal Antibody Binding Terminus (uABT) to
Recruit Endogenous Antibodies To Cells Expressing CD38 Demonstrates
Anti-Multiple Myeloma Activity in vitro and ex-vivo
Against Patient Tumor Cells
Date & Time: Monday, December
9, 2019 from 6:00 p.m. - 8:00
p.m.
Session: 652. Myeloma: Pathophysiology and Pre-Clinical
Studies, excluding Therapy: Poster III
Abstract: 4411
Location: Orange County
Convention Center, Hall B
Presenter: Ann Marie
Rossi
According to multiple lines of evidence including ex vivo data
in patient bone marrow samples, Kleo's CD38–ARMs are able to kill
MM cells by antibody dependent cellular cytotoxicity (ADCC) without
depleting CD38-expressing immune cells, unlike existing antibodies
such as Daratumumab. Combined with the in vivo efficacy data
presented elsewhere, these data establish the therapeutic potential
of CD38-ARM, and for the first time, the ARM platform's ability to
generate therapeutic agents tailored to a specific indication.
Title: A Novel Class of Bifunctional Immunotherapeutic
That Exploits a Universal Antibody Binding Terminus (uABT) to
Recruit Endogenous Antibodies To Cell Expressing CD38 Demonstrate
in vivo Efficacy in Three Distinct Animal Models
Date & Time: Saturday, December
7, 2019, 5:30 p.m. – 7:30
p.m.
Session: 652. Myeloma: Pathophysiology and Pre-Clinical
Studies, excluding Therapy: Poster I
Abstract: 1820
Location: Orange County
Convention Center, Hall B
Presenter: Anna Bunin
This presentation outlines how CD38-ARM compounds are
therapeutically active in three distinct in vivo models. This data
provides strong evidence for the CD38-ARM's capacity to engage both
macrophage and NK cells effector functions, providing a foundation
to advance Kleo's compounds towards the clinic. The results also
showed that CD38-ARM compounds engage a variety of effector
mechanisms involved in tumor clearance and tumor growth delay,
indicating therapeutic potential across a wide range of clinical
settings. Overall, the data demonstrated the value of ARM compounds
as a platform to develop compounds tailored to a specific
indication.
These ASH abstracts are now available at www.hematology.org. The
poster presentations will include additional data not available in
the abstract.
About Kleo Pharmaceuticals, Inc.
Kleo Pharmaceuticals
is a unique immuno-oncology company developing next-generation
bispecific compounds designed to emulate or enhance the activity of
biologics based on the groundbreaking research of its scientific
founder Dr. David Spiegel at Yale
University. Similar to complex biologic drugs, Kleo's
compounds recruit the immune system to destroy cancer cells, with
the advantage of being smaller and more versatile, leading to
potentially improved safety and efficacy over biologics. They are
also much faster and less costly to design and produce,
particularly against novel targets. Kleo is advancing several drug
candidates based on its proprietary technology platforms, all of
which are modular in design and enable rapid generation of novel
immunotherapies that can be optimized against certain cancers, or
enhance the properties of existing immunotherapies. These include
Antibody Recruiting Molecules (ARMs), Synthetic Antibody Mimics
(SyAMs) and Monoclonal Antibody Therapy Enhancers (MATEs). Biohaven
Pharmaceutical Holding Company (NYSE:BHVN) and PeptiDream Inc.
(Nikkei:PPTDF) are investors in Kleo Pharmaceuticals. For
more information visit http://kleopharmaceuticals.com.
Forward-Looking Statements
This news release includes
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements involve substantial risks and uncertainties, including
statements that are based on the current expectations and
assumptions of the Company's management. All statements, other than
statements of historical facts, included in this press release
regarding the Company's plans and objectives, expectations and
assumptions of management are forward-looking statements. The use
of certain words, including the words "estimate," "project,"
"intend," "expect," "believe," "anticipate," "will," "plan,"
"could," "may" and similar expressions are intended to identify
forward-looking statements. The forward-looking statements are made
as of this date and the Company does not undertake any obligation
to update any forward-looking statements, whether as a result of
new information, future events or otherwise.
CONTACT INFORMATION
Tiberend Strategic Advisors, Inc.
Maureen McEnroe, CFA (Investors)
212-375-2664
mmcenroe@tiberend.com
Ingrid Mezo (Media)
646-604-5150
imezo@tiberend.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/kleo-pharmaceuticals-presents-preclinical-data-supporting-development-of-its-cd38-arm-a-novel-immuno-therapeutic-at-american-society-of-hematology-ash-annual-meeting-300952793.html
SOURCE Kleo Pharmaceuticals, Inc.